Spectranetics Corp  

(Public, NASDAQ:SPNC)   Watch this stock  
11.75
-0.35 (-2.89%)
Feb 11 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.53 - 12.44
52 week 10.65 - 37.04
Open 12.00
Vol / Avg. 0.00/703,480.00
Mkt cap 504.32M
P/E     -
Div/yield     -
EPS -1.51
Shares 42.64M
Beta 1.26
Inst. own 113%
Feb 25, 2016
Q4 2015 Spectranetics Corp Earnings Call - 4:30PM EST - Add to calendar
Feb 25, 2016
Q4 2015 Spectranetics Corp Earnings Release - 4:00PM EST - Add to calendar
Jan 13, 2016
Spectranetics Corp at JPMorgan Healthcare Conference - Webcast
Dec 1, 2015
Spectranetics Corp at Piper Jaffray Healthcare Conference - Webcast
Nov 19, 2015
Spectranetics Corp at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 18, 2015
Spectranetics Corp at Stifel Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -23.50% -19.96%
Operating margin -20.15% -18.03%
EBITD margin - 0.63%
Return on average assets -13.13% -11.96%
Return on average equity -44.30% -23.23%
Employees 753 -
CDP Score - -

Address

9965 Federal Dr
COLORADO SPRINGS, CO 80921-3822
United States - Map
+1-719-6338333 (Phone)
+1-877-4472022 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. The Company offers excimer laser system known as the CVX-300. Its Vascular Intervention business unit includes a range of peripheral and cardiac laser catheters for ablation of blockages in arteries above and below the knee (peripheral atherectomy) and within coronary arteries (coronary atherectomy); support catheters to facilitate crossing of coronary and peripheral arterial blockages (crossing solutions); and thrombectomy catheters for the removal of thrombus (thrombus management). The Company’s Lead Management business unit includes excimer laser sheaths, non-laser sheaths and cardiac lead management accessories.

Officers and directors

R. John Fletcher Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Scott William Drake President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Stacy McMahan Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Shahriar Matin Chief Operating Officer
Age: 40
Bio & Compensation  - Reuters
Paul Gardon Senior Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Kimberly McIntosh Bridges Senior Vice President - Sales and Marketing of Vascular Intervention
Age: 41
Bio & Compensation  - Reuters
Donna Ford-Serbu Senior Vice President - Sales and Marketing of Lead Management
Age: 46
Bio & Compensation  - Reuters
Robert Michael Fuchs Senior Vice President, Global Head - Human Resources
Age: 48
Bio & Compensation  - Reuters
Austin B. Byrd Chief Compliance Officer, Vice President
Age: 49
Bio & Compensation  - Reuters
Wade A. Bowe Vice President - Research & Development
Age: 44
Bio & Compensation  - Reuters